Patents by Inventor James Peach
James Peach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210115107Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.Type: ApplicationFiled: November 20, 2020Publication date: April 22, 2021Inventors: Robert James Peach, Joseph Naemura, Peter S. Linsley, Jurgen Bajorath
-
Publication number: 20200369744Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.Type: ApplicationFiled: January 31, 2020Publication date: November 26, 2020Inventors: Glen Eugene Mikesell, Han Chang, Robert James Peach
-
Patent number: 10590183Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.Type: GrantFiled: April 12, 2019Date of Patent: March 17, 2020Assignee: Bristol-Myers Squibb CompanyInventors: Glen Eugene Mikesell, Han Chang, Robert James Peach
-
Publication number: 20200079835Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.Type: ApplicationFiled: July 18, 2019Publication date: March 12, 2020Inventors: Glen Eugene Mikesell, Han Chang, Joshua N. Finger, Guchen Yang, Robert James Peach, Henry Shen
-
Publication number: 20200005565Abstract: A system and method for controlling usage of a machine by an operator includes a card containing identity information related to the operator selectively in communication with an access device and a first server is in communication with the access device. The identity information is communicated to the access device. The first server includes training information for at least one operator and at least one training certificate. Identity information is communicated to the first server from the access device and the first server compares the identity information to the training information to identify whether the operator has a training certificate for the selected machine. The first server communicates to the access device that the operator does or does not have a training certificate for the selected machine. The access device permits instruction from the operator to the machine when the operator does have a training certificate for the selected machine.Type: ApplicationFiled: September 9, 2019Publication date: January 2, 2020Inventors: James Peach, Pavel Mikhailovich Podgurskiy
-
Patent number: 10410443Abstract: A system and method for controlling usage of a machine by an operator includes a card containing identity information related to the operator selectively in communication with an access device and a first server is in communication with the access device. The identity information is communicated to the access device. The first server includes training information for at least one operator and at least one training certificate. Identity information is communicated to the first server from the access device and the first server compares the identity information to the training information to identify whether the operator has a training certificate for the selected machine. The first server communicates to the access device that the operator does or does not have a training certificate for the selected machine. The access device permits instruction from the operator to the machine when the operator does have a training certificate for the selected machine.Type: GrantFiled: September 30, 2016Date of Patent: September 10, 2019Assignee: Schlumberger Technology CorporationInventors: James Peach, Pavel Mikhailovich Podgurskiy
-
Patent number: 10400023Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.Type: GrantFiled: August 5, 2016Date of Patent: September 3, 2019Assignee: Bristol-Myers Squibb CompanyInventors: Glen Eugene Mikesell, Han Chang, Robert James Peach
-
Publication number: 20190248868Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.Type: ApplicationFiled: April 12, 2019Publication date: August 15, 2019Inventors: Glen Eugene Mikesell, Han Chang, Robert James Peach
-
Patent number: 10370428Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.Type: GrantFiled: August 4, 2017Date of Patent: August 6, 2019Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Robert James Peach, Joseph Naemura, Peter S. Linsley, Jurgen Bajorath
-
Publication number: 20190185538Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.Type: ApplicationFiled: December 20, 2018Publication date: June 20, 2019Inventors: Robert James Peach, Joseph Naemura, Peter S. Linsley, Jurgen Bajorath
-
Patent number: 10308702Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.Type: GrantFiled: July 25, 2016Date of Patent: June 4, 2019Assignee: Bristol-Myers Squibb ComapnyInventors: Glen Eugene Mikesell, Han Chang, Robert James Peach
-
Publication number: 20180293822Abstract: A system and method for controlling usage of a machine by an operator includes a card containing identity information related to the operator selectively in communication with an access device and a first server is in communication with the access device. The identity information is communicated to the access device. The first server includes training information for at least one operator and at least one training certificate. Identity information is communicated to the first server from the access device and the first server compares the identity information to the training information to identify whether the operator has a training certificate for the selected machine. The first server communicates to the access device that the operator does or does not have a training certificate for the selected machine.Type: ApplicationFiled: September 30, 2016Publication date: October 11, 2018Inventors: James Peach, Pavel Mikhailovich Podgurskiy
-
Patent number: 10052360Abstract: The present invention relates to compositions and methods for treating autoimmune diseases by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.Type: GrantFiled: February 19, 2016Date of Patent: August 21, 2018Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Robert Cohen, Suzette Belder-Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
-
Publication number: 20180134764Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.Type: ApplicationFiled: August 4, 2017Publication date: May 17, 2018Inventors: Robert James PEACH, Joseph Naemura, Peter S. Linsley, Jurgen Bajorath
-
Publication number: 20170369549Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.Type: ApplicationFiled: August 4, 2017Publication date: December 28, 2017Inventors: Robert James PEACH, Joseph Naemura, Peter S. Linsley, Jurgen Bajorath
-
Patent number: 9758565Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.Type: GrantFiled: May 29, 2014Date of Patent: September 12, 2017Assignee: Bristol-Myers Squibb CompanyInventors: Robert James Peach, Joseph Naemura, Peter S. Linsley, Jurgen Bajorath
-
Publication number: 20170190759Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.Type: ApplicationFiled: July 25, 2016Publication date: July 6, 2017Inventors: Glen Eugene MIKESELL, Han Chang, Robert James Peach
-
Publication number: 20160340408Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.Type: ApplicationFiled: August 5, 2016Publication date: November 24, 2016Inventors: Glen Eugene MIKESELL, Han Chang, Robert James Peach
-
Patent number: 9409970Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.Type: GrantFiled: February 12, 2014Date of Patent: August 9, 2016Assignee: Bristol-Myers Squibb CompanyInventors: Glen Eugene Mikesell, Han Chang, Joshua N. Finger, Guchen Yang, Robert James Peach, Henry Shen
-
Patent number: 9399052Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.Type: GrantFiled: February 11, 2014Date of Patent: July 26, 2016Assignee: Bristol-Myers Squibb CompanyInventors: Glen Eugene Mikesell, Henry Shen, Han Chang, Joshua N. Finger, Guchen Yang, Robert James Peach